Cargando…

Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review

BACKGROUND: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbic, Milena, Sretenovic, Jasmina, Zivkovic, Vladimir, Jakovljevic, Vladimir, Nikolic Turnic, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362213/
https://www.ncbi.nlm.nih.gov/pubmed/37484720
http://dx.doi.org/10.18502/ijph.v52i5.12704
_version_ 1785076375988731904
author Corbic, Milena
Sretenovic, Jasmina
Zivkovic, Vladimir
Jakovljevic, Vladimir
Nikolic Turnic, Tamara
author_facet Corbic, Milena
Sretenovic, Jasmina
Zivkovic, Vladimir
Jakovljevic, Vladimir
Nikolic Turnic, Tamara
author_sort Corbic, Milena
collection PubMed
description BACKGROUND: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic disease. PDE-5 inhibitors can through different models and mechanisms induce vasodilation, decrease apoptosis and cell proliferation, and they are widely present in various tissues that make them promising targets in a range of cardiovascular diseases. METHODS: PubMed was explored to identify papers published from 1990–2019, presenting data for the most used PDE-5 inhibitors (sildenafil, tadalafil or vardenafil) in treatment of cardiovascular diseases. RESULTS: This article analyses the therapeutic potentials of PDE-5 inhibitors in cardiovascular diseases and discusses mechanisms, possible risks and limitations. Comparable to earlier studies, newer studies suggest cardioprotective effects of PDE-5 inhibitors, which include different models and mechanisms and do not indicate an increased rate of significant cardiovascular adverse reactions. Dissimilarity in the pharmacokinetics and pharmacodynamics of PDE-5 inhibitors are significant to their risk- benefit profile and clinical use. Some of the studies suggesting infarct size reduction after PDE-5 inhibition described the especially close dose-effect relation, other studies dosage adaptation in drug- drug interactions. CONCLUSION: PDE-5 inhibitors indicate the encouraging useful effects by ischemia/reperfusion injury, myocar-dial infarction, cardiac hypertrophy, cardiomyopathy and systolic and diastolic congestive heart failure. Therefore, this and similar reviews can help for additional clinical targeting in the therapy of cardiovascular diseases.
format Online
Article
Text
id pubmed-10362213
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-103622132023-07-23 Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review Corbic, Milena Sretenovic, Jasmina Zivkovic, Vladimir Jakovljevic, Vladimir Nikolic Turnic, Tamara Iran J Public Health Review Article BACKGROUND: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic disease. PDE-5 inhibitors can through different models and mechanisms induce vasodilation, decrease apoptosis and cell proliferation, and they are widely present in various tissues that make them promising targets in a range of cardiovascular diseases. METHODS: PubMed was explored to identify papers published from 1990–2019, presenting data for the most used PDE-5 inhibitors (sildenafil, tadalafil or vardenafil) in treatment of cardiovascular diseases. RESULTS: This article analyses the therapeutic potentials of PDE-5 inhibitors in cardiovascular diseases and discusses mechanisms, possible risks and limitations. Comparable to earlier studies, newer studies suggest cardioprotective effects of PDE-5 inhibitors, which include different models and mechanisms and do not indicate an increased rate of significant cardiovascular adverse reactions. Dissimilarity in the pharmacokinetics and pharmacodynamics of PDE-5 inhibitors are significant to their risk- benefit profile and clinical use. Some of the studies suggesting infarct size reduction after PDE-5 inhibition described the especially close dose-effect relation, other studies dosage adaptation in drug- drug interactions. CONCLUSION: PDE-5 inhibitors indicate the encouraging useful effects by ischemia/reperfusion injury, myocar-dial infarction, cardiac hypertrophy, cardiomyopathy and systolic and diastolic congestive heart failure. Therefore, this and similar reviews can help for additional clinical targeting in the therapy of cardiovascular diseases. Tehran University of Medical Sciences 2023-05 /pmc/articles/PMC10362213/ /pubmed/37484720 http://dx.doi.org/10.18502/ijph.v52i5.12704 Text en Copyright © 2023 Corbic et al. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Review Article
Corbic, Milena
Sretenovic, Jasmina
Zivkovic, Vladimir
Jakovljevic, Vladimir
Nikolic Turnic, Tamara
Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
title Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
title_full Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
title_fullStr Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
title_full_unstemmed Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
title_short Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
title_sort phosphodiesterase-5 inhibitors as therapeutics for cardiovascular diseases: a brief review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362213/
https://www.ncbi.nlm.nih.gov/pubmed/37484720
http://dx.doi.org/10.18502/ijph.v52i5.12704
work_keys_str_mv AT corbicmilena phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview
AT sretenovicjasmina phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview
AT zivkovicvladimir phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview
AT jakovljevicvladimir phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview
AT nikolicturnictamara phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview